Efficient microfluidic negative enrichment of circulating tumor cells in blood using roughened PDMS

The Analyst ◽  
2015 ◽  
Vol 140 (10) ◽  
pp. 3565-3572 ◽  
Author(s):  
L. Diéguez ◽  
M. A. Winter ◽  
K. J. Pocock ◽  
K. E. Bremmell ◽  
B. Thierry
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Recovery ◽  
P Depletion

Depletion of >99.7% WBCs enabling tumor cell recovery from blood with nano-rough PDMS microfluidic negative enrichment devices functionalised with anti-CD45.

Circulating tumor cell detection using a parallel flow micro-aperture chip system

Lab on a Chip ◽  
2015 ◽  
Vol 15 (7) ◽  
pp. 1677-1688 ◽  
Author(s):  
Chun-Li Chang ◽  
Wanfeng Huang ◽  
Shadia I. Jalal ◽  
Bin-Da Chan ◽  
Aamer Mahmood ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Cell ◽  
Parallel Flow ◽  
Cell Detection ◽  
Tumor Cell Detection ◽  
System P

A parallel flow micro-aperture chip system for detection of circulating tumor cells.

scholarly journals Microfluidics-enabled rapid manufacturing of hierarchical silica-magnetic microflower toward enhanced circulating tumor cell screening

2018 ◽  
Vol 6 (12) ◽  
pp. 3121-3125 ◽  
Author(s):  
Nanjing Hao ◽  
Yuan Nie ◽  
Amogha Tadimety ◽  
Ting Shen ◽  
John X. J. Zhang
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Cell ◽  
Rapid Manufacturing ◽  
Screening Efficiency

Microfluidics-enabled rapid manufacturing of a hierarchical silica-magnetic microflower was developed for improving the screening efficiency of circulating tumor cells.

scholarly journals Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression

2020 ◽  
Vol 21 (4) ◽  
pp. 1475
Author(s):  
Vera Cappelletti ◽  
Elena Verzoni ◽  
Raffaele Ratta ◽  
Marta Vismara ◽  
Marco Silvestri ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Response Prediction ◽  
Surface Proteins ◽  
Cell Recovery ◽  
Epithelial Cell Surface

Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal cell carcinoma (RCC) shows low expression of epithelial markers hindering CTC-enrichment approaches exploiting epithelial cell surface proteins. In 21 blood samples serially collected from 10 patients with metastatic RCC entering the TARIBO trial, we overcame this limitation using the marker-independent Parsortix™ approach for CTC-enrichment coupled with positive and negative selection with the DEPArray™ with single cell recovery and analysis for copy number alterations (CNA) by next generation sequencing NGS. Two CTC subpopulations were identified: epithelial CTC (eCTC) and non-conventional CTC (ncCTC) lacking epithelial and leukocyte markers. With a threshold ≥1CTC/10 mL of blood, the positivity rates were 28% for eCTC, 62% for ncCTCs, and 71% considering both CTC types. In two patients with detectable eCTCs at baseline, progression free survival was less than 5 months. In an index case, hierarchical structure by translational oncology (TRONCO) identified three clones among 14 CTCs collected at progression and at baseline, each containing cells with a 9p21.3loss, a well-known metastasis driving subclonal alteration. CTCs detection in RCC can be increased by marker-independent approaches, and CTC molecular characterization can allow detection of subclonal events possibly related to tumor progression.

scholarly journals Application of circulating tumor cells scope technique on circulating tumor cell research

2014 ◽  
Vol 2 (1) ◽  
pp. 8 ◽  
Author(s):  
Dawei Yang ◽  
Lijie Wang ◽  
Xiaochen Tian
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Cell

Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10599-10599 ◽  
Author(s):  
Volkmar Mueller ◽  
Sabine Riethdorf ◽  
Brigitte Kathrin Rack ◽  
Wolfgang Janni ◽  
Peter A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Elevated Serum ◽  
Metastatic Breast ◽  
Serum Levels ◽  
Her2 Status ◽  
Cellsearch System ◽  
Prognostic Information

10599 Background: Circulating tumor cells (CTC) reflect an aggressive tumor behavior by hematogenous tumor cell dissemination. Overexpression of HER2 in breast cancer (BC) is associated with increased angiogenesis and therefore potentially linked to increased hematogenous tumor cell spread. The aim of the analysis was to investigate whether concentrations of serum HER2 (sHER2) deliver prognostic information in the context of CTC detection in metastatic BC patients. Methods: Blood was obtained in a prospective multicenter setting from 254 patients with metastatic BC at the time of disease progression. sHER2 was determined using a commercial ELISA-kit (Wilex). CTC were detected with the CellSearch system (Veridex). Patients received systemic treatment according to national and international guidelines including HER2-targeted treatment. Results: Five or more CTC were detected in 122 of 245 evaluable patients (49.8%).119 of 251 (47%) metastatic patients had serum sHER2 levels above 15ng/mL. Median PFS was 9.2 months (95%-CI: 9.9 – 13.0 mths) with elevated sHER2 versus 11.4 mths (9.9 – 13.0 mths) with non-elevated levels (p=0.07). OS was 17.4 mths (14.6 – 20.3 mths) vs. 26.5 mths (23.1-29.8 mths; p<0.01). In patients with 5 or more CTC, serum levels were above the cut-off for sHER2 in 61% vs. 33% in those with less than 5 CTC (p< 0.01). Patients with elevated sHER and 5 or more CTC hat a PFS of 9.1 mths (7.2 – 11.1 mths) and a OS of 14.5 mths (11.8 – 17.2 mths), those with non-elevated sHER2 and less than 5 CTC a PFS of 12.1 (10.1 – 14.1 mths) and a OS of 29.5 month (25.4 – 33.6 mths) (p=0.15 for PFS and p< 0.01 for OS). Including sHER2, CTC and established prognostic factors in the multivariate analysis, the presence of CTC, line of therapy, ER and HER2 status of the primary tumor remained independent predictors of OS. Conclusions: Elevated serum levels of sHER2 are associated with the presence of CTC and indicate poor clinical outcome. However, sHER2 has no independent prognostic value when presence of CTC were taken into account.

scholarly journals Cytopathologic Detection of Circulating Tumor Cells Using the Isolation by Size of Epithelial Tumor Cell Method

2011 ◽  
Vol 135 (1) ◽  
pp. 146-156 ◽  
Author(s):  
Véronique J. Hofman ◽  
Marius I. Ilie ◽  
Christelle Bonnetaud ◽  
Eric Selva ◽  
Elodie Long ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Epithelial Tumor ◽  
Cell Method ◽  
Epithelial Tumor Cell

scholarly journals Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer

2018 ◽  
Vol 24 (7) ◽  
pp. 810-818 ◽  
Author(s):  
Daniel Brungs ◽  
David Lynch ◽  
Alison WS Luk ◽  
Elahe Minaei ◽  
Marie Ranson ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Cell ◽  
Cell Isolation ◽  
Gastroesophageal Cancer ◽  
Prognostic Association
Sign in / Sign up

Export Citation Format

Share Document